Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
97.43
+0.34 (+0.35%)
Streaming Delayed Price
Updated: 9:56 AM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
122,462
Open
97.08
Bid (Size)
97.43 (1)
Ask (Size)
97.44 (5)
Prev. Close
97.09
Today's Range
96.92 - 97.43
52wk Range
92.19 - 108.78
Shares Outstanding
N/A
Dividend Yield
3.56%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
April 29, 2024
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...
Via
Benzinga
Exposures
Product Safety
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
April 29, 2024
The company is projected to bring in increasing sales through at least 2029.
Via
Investor's Business Daily
Performance
YTD
-3.53%
-3.53%
1 Month
+1.63%
+1.63%
3 Month
-9.75%
-9.75%
6 Month
+3.91%
+3.91%
1 Year
-4.98%
-4.98%
More News
Read More
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
April 28, 2024
Via
Talk Markets
What's Going On With Pfizer Stock On Thursday?
April 25, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
April 23, 2024
Via
Investor's Business Daily
Looking At Novartis's Recent Unusual Options Activity
April 11, 2024
Via
Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
Via
Investor's Business Daily
Why Novartis Stock Topped the Market on Tuesday
April 23, 2024
Via
The Motley Fool
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
April 23, 2024
Via
Benzinga
Exposures
Product Safety
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
April 23, 2024
Via
InvestorPlace
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
April 23, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
April 23, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
April 23, 2024
Via
Benzinga
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
April 23, 2024
Via
Benzinga
Topics
Bonds
Exposures
Debt Markets
Top Analyst Reports For Novartis, American Express & ConocoPhillips
April 22, 2024
Via
Talk Markets
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
April 19, 2024
Via
Investor's Business Daily
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Via
Benzinga
Exposures
Product Safety
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
April 17, 2024
Via
Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
April 17, 2024
Via
The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Via
Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
April 16, 2024
Via
Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
April 14, 2024
Via
The Motley Fool
Topics
ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
April 11, 2024
Via
Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.